Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age

Hormone Research in Paediatrics

Volumn 79, Issue 6, 2013, Pages 333-340

  Alcausin, M B ^a,g,h   Briody, J ^e   Pacey, V ^d   Ault, J ^c   McQuade, M ^b   Bridge, C ^f   Engelbert, R H H ^i,j   Sillence, D O ^a,g,h   Munns, C F ^b,h  

^a Clinical Genetics   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c Sydney Children's Hospital Network Westmead Campus   (Australia)

^d Physiotherapy Peter James Centre Eastern Health   (Australia)

^e Nuclear Medicine   (Australia)

^f Sydney Children's Hospital Network Westmead Campus   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ Physiotherapy   (Australia)

^j UNIVERSITY OF AMSTERDAM   (Netherlands)

more..

Author keywords

Children; Early treatment; Motor development; Osteogenesis imperfecta; Pamidronate

Indexed keywords

CALCIUM; PAMIDRONIC ACID; VITAMIN D;

ANTHROPOMETRY; ARTICLE; BIOCHEMISTRY; BONE DENSITY; BONE DEVELOPMENT; BONE FRAGILITY; CLINICAL ARTICLE; HUMAN; INFORMATION PROCESSING; LONG BONE; LUMBAR SPINE; MEDICAL HISTORY; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; SITTING; CHILD; COMPRESSION FRACTURE; DISEASE SEVERITY; FEMALE; FEVER; FRACTURE; MALE; SPINE FRACTURE; VOMITING; WALKING;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CHILD, PRESCHOOL; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; LUMBAR VERTEBRAE; MALE; MOTOR SKILLS; OSTEOGENESIS IMPERFECTA; RETROSPECTIVE STUDIES;

EID: 84880573008     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000351374     Document Type: Article

References (34)

1. Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM: Classification of osteogenesis imperfecta revisited. Eur J Med Genet 2010; 53: 1-5.
2. van Dijk FS, Byers PH, Dalgleish R, Malfait F, Maugeri A, Rohrbach M, et al: EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. Eur J Hum Genet 2012; 20:11-19.
3. Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R, LeMerrer M, et al: Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet A 2011; 155A:943-968.
4. Munns CF, Sillence DO: Osteogenesis Imperfecta (and other Disorders of Bone Matrix), ed 6. Philadelphia, Churchill-Livingstone, 2013.
5. Sillence D: Osteogenesis imperfect; in: Brenner's Online Encyclopedia of Genetics, ed 2. Amsterdam, Elsevier, 2012.
6. Semler O, Garbes L, Keupp K, Swan D, Zimmermann K, Becker J, et al: A mutation in the 5'-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyper-plastic callus. A m J Hum Genet 2012; 91: 349-357.
7. Russell RG: Bisphosphonates: the first 40 years. Bone 2011; 49:2-19.
8. Astrom E, Soderhall S: Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002; 86:356-364. (Pubitemid 34478233)
9. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R: Cyclic administration of pamidronate in children with severe osteo-genesis imperfecta. N Engl J Med 1998; 339: 947-952. (Pubitemid 28455096)
10. Rauch F, Plotkin H, Zeitlin L, Glorieux FH: Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 2003; 18:610-614. (Pubitemid 36899310)
11. Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH: Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone 2006; 39:901-906. (Pubitemid 44311714)
12. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH: Osteogenesis imperfecta types I, III and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 2003; 88:986-992. (Pubitemid 36337744)
13. Munns CF, Rauch F, Travers R, Glorieux FH: Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res 2005; 20:1235-1243. (Pubitemid 40863813)
14. DiMeglio LA, Ford L, McClintock C, Peacock M: Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 2004; 35: 1038-1045. (Pubitemid 39487349)
15. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, et al: Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000; 85:1846-1850. (Pubitemid 32269287)
16. Engelbert RH, Uiterwaal CS, Gulmans VA, Pruijs HE, Helders PJ: Osteogenesis imper-fecta: profiles of motor development as assessed by a postal questionnaire. Eur J Pediatr 2000; 159:615-620. (Pubitemid 30469450)
17. Munns C, Zacharin MR, Rodda CP, Batch JA, Morley R, Cranswick NE, et al: Prevention and treatment of infant and childhood vitamin D deficiency in Australia and New Zealand: a consensus statement. Med J Aust 2006; 185:268-272. (Pubitemid 44382878)
18. CDC: Growth Charts for the the United States 2000: Methods and Development, 2000.
19. Smith-Bindman R, Cummings SR, Steiger P, Genant HK: A comparison of morphometric definitions of vertebral fracture. J Bone Miner Res 1991; 6:25-34.
20. Lu PW, Briody JN, Ogle GD, Morley K, Humphries IR, Allen J, et al: Bone mineral density of total body, spine, and femoral neck in children and young adults: a cross-sectional and longitudinal study. J Bone Miner Res 1994; 9:1451-1458. (Pubitemid 24268858)
21. Ogle GD, Allen JR, Humphries IR, Lu PW, Briody JN, Morley K, et al: Body-composition assessment by dual-energy X-ray absorptiometry in subjects aged 4-26 years. Am J Clin Nutr 1995; 61:746-753.
22. Alos N, Eugène D, Chabot G, Gougeon M, Dubois J: Pediatric reference data for bone mineral density of the lumbar spine in infants and young children. J Bone Miner Res 2006; 21(suppl 1):S327.
23. Astrom E, Jorulf H, Soderhall S: Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta. Arch Dis Child 2007; 92:332-338. (Pubitemid 46535517)
24. Zeitlin L, Fassier F, Glorieux FH: Modern approach to children with osteogenesis imperfecta. J Pediatr Orthopaedics Part B 2003; 12: 77-87. (Pubitemid 36268536)
25. Chiasson R, Munns C, Zeitlin L: Interdisciplinary Treatment Approach for Children with Osteogenesis Imperfecta. Montreal, Shriners Hospital for Children (Canada), 2004.
26. Munns CF, Rauch F, Mier RJ, Glorieux FH: Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 2004; 35:231-234. (Pubitemid 38789169)
27. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB: Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000; 15:613-620. (Pubitemid 30174014)
28. Goksen D, Coker M, Darcan S, et al: Low-dose intravenous pamidronate treatment in osteogenesis imperfecta. Turk J Pediatr 2006; 48: 124-129. (Pubitemid 44070362)
29. Senthilnathan S, Walker E, Bishop NJ: Two doses of pamidronate in infants with osteogenesis imperfecta. Arch Dis Child 2008; 93: 308-400.
30. Munns CF, Rauch F, Travers R, Glorieux FH: Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcomes. J Bone Miner Res 2005; 20:1235-1243. (Pubitemid 40863813)
31. McAllion SJ, Paterson CR: Causes of death in osteogenesis imperfecta. J Clin Pathol 1996; 49:627-630. (Pubitemid 26264386)
32. Engelbert RH, Uiterwaal CS, Gulmans VA, Pruijs H, Helders PJ: Osteogenesis imperfecta in childhood: prognosis for walking. J Pediatr 2000; 137:397-402.
33. Montpetit K, Plotkin H, Rauch F, Bilodeau N, Cloutier S, Rabzel M, et al: Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics 2003; 111:e601-e603.
34. Feldman AB, Haley SM, Coryell J: Concurrent and construct validity of the Pediatric Evaluation of Disability Inventory. Phys Ther 1990; 70:602-610. (Pubitemid 20330188)